Welcome to our dedicated page for BETTER THERAPEUTICS news (Ticker: BTTX), a resource for investors and traders seeking the latest updates and insights on BETTER THERAPEUTICS stock.
Better Therapeutics Inc. (BTTX) is at the forefront of developing prescription digital therapeutics aimed at treating chronic diseases. The company, formerly known as Farewell, leverages a unique combination of software, human coaching enhanced by artificial intelligence, and advanced analytics to address the underlying behaviors causing most chronic conditions. This innovative approach offers scalable solutions capable of impacting millions of lives.
Better Therapeutics' digital therapeutics are grounded in solid evidence and align with existing clinical treatment guidelines. They can be integrated with other interventions or used independently, providing flexible and effective treatment options. The company's non-drug solutions are pivotal in reducing the health and financial burdens of chronic diseases on individuals, healthcare payers, and the broader healthcare system.
Recent achievements include significant advancements in their AI-driven coaching systems and the successful integration of their digital therapeutics into various healthcare settings. Better Therapeutics is continually expanding its partnerships and collaborations to further enhance the reach and effectiveness of its products.
The company's financial health reflects steady growth, driven by its innovative products and expanding market presence. Better Therapeutics remains committed to advancing its mission of improving chronic disease management through cutting-edge digital solutions.
Better Therapeutics announced the successful completion of its pivotal clinical trial for BT-001, a digital therapeutic aimed at treating type 2 diabetes (T2D). The results showed sustained improvements in A1c levels, with a significant reduction of 1.3% in half of the participants after 180 days. The company plans to submit a de novo classification request to the FDA in Q3 2022 for marketing authorization. This could position BT-001 as the first prescription digital therapeutic for T2D, addressing the disease's root causes.
Better Therapeutics (NASDAQ: BTTX) will host a conference call and webcast on July 28, 2022, at 8:30 a.m. ET, to discuss the results of its pivotal clinical trial of BT-001 for type 2 diabetes after 180 days of treatment. The management team will be joined by Marc Bonaca, MD, MPH, from the University of Colorado. This trial is part of their initiative to develop nutritional cognitive behavioral therapy aimed at addressing cardiometabolic diseases.
Better Therapeutics, Inc. (NASDAQ: BTTX) announced the publication of a manuscript in Clinical Cardiology detailing the pivotal trial design for BT-001 in treating type 2 diabetes (T2D). This is the first randomized controlled trial of a prescription digital therapeutic for T2D. Positive primary endpoint data were reported in March, with secondary data expected soon. The trial included 669 diverse T2D patients, targeting accessibility to behavioral therapy through a mobile app. The company plans to submit a de novo classification request to the FDA by Q3 2022.
Better Therapeutics, Inc. (NASDAQ: BTTX), a leading prescription digital therapeutics company, announced that CEO Kevin Appelbaum will participate in the Commercializing Prescription Digital Therapeutics panel at the Cowen 7th Annual FutureHealth Conference on June 23, 2022, at 12:40 p.m. ET. This event will focus on their innovative approach to treating cardiometabolic diseases through nutritional cognitive behavioral therapy (nCBT). Better Therapeutics aims to provide FDA-regulated software solutions that address the root causes of conditions like type 2 diabetes and heart disease.
Better Therapeutics, Inc. (NASDAQ: BTTX) will participate in a webinar titled Unlocking the Value of Digital Prescription Therapeutics on June 16, 2022, at 10:00 a.m. ET. The event, hosted by Cowen, will discuss promising results from the pivotal clinical trial of BT-001, a digital therapeutic for type 2 diabetes that significantly outperformed traditional pharmaceutical treatments in reducing A1c levels. Key speakers include Mark Berman, Prapti Mehta, and Marc Bonaca, who will elaborate on the implications of these findings for current diabetes treatment.
Better Therapeutics (NASDAQ: BTTX) received its first patent from the USPTO, granting 20 years of exclusivity for key features of its digital therapeutics platform targeting cardiometabolic diseases. The patent, titled “SYSTEM, METHODS, AND APPARATUSES FOR MANAGING DATA FOR ARTIFICIAL INTELLIGENCE SOFTWARE AND MOBILE APPLICATIONS IN DIGITAL HEALTH THERAPEUTICS,” was awarded on June 7, 2022. This innovation enables the use of machine learning to personalize treatment regimens. The company plans to file for FDA approval of its first product, BT-001, for type 2 diabetes, following a pivotal clinical trial completion.
Better Therapeutics (NASDAQ: BTTX) has announced the appointment of Frank Karbe as President and CEO starting July 5, 2022. He replaces co-founder Kevin Appelbaum, who will continue until then. Karbe brings extensive experience, having previously raised approximately $2 billion at Myovant Sciences and over $4 billion at Exelixis. The company is poised for a potential FDA submission of its first digital therapeutic for type 2 diabetes, supported by positive trial data indicating significant improvements in patient outcomes.
Better Therapeutics (NASDAQ: BTTX) is set to host a virtual symposium on June 1, 2022, from 12:00 to 1:00 p.m. ET, focusing on the application of nutritional cognitive behavioral therapy (nCBT) for treating type 2 diabetes. Medical experts will discuss recent updates to the American Diabetes Association (ADA) guidelines, emphasizing the role of digital therapeutics in patient care. The event will review clinical trial results of Better Therapeutics' BT-001 platform, which showed notable A1c reductions beyond traditional treatments. Registration is available online.
Better Therapeutics, Inc. (NASDAQ: BTTX) announced positive results from its pivotal trial of BT-001 for type 2 diabetes, achieving its primary endpoint after 90 days of treatment. This marks a first-in-class digital therapeutic approach, with FDA classification filing expected in Q3 2022, pending supportive data. The company also initiated a novel study on nutritional Cognitive Behavior Therapy for Nonalcoholic Fatty Liver Disease. However, R&D and operational expenses rose significantly, with Q1 2022 R&D expenses at $3.7 million, highlighting financial pressures despite clinical progress.
Better Therapeutics (NASDAQ: BTTX) announced it will release its Q1 2022 financial results before the market opens on May 13, 2022. A conference call for a business update will follow at 8:30 a.m. Eastern Time on the same day. The company specializes in prescription digital therapeutics aimed at addressing cardiometabolic diseases through nutritional cognitive behavioral therapy (nCBT). Their proprietary platform aims to create FDA-regulated solutions for conditions like type 2 diabetes and heart disease, which could enhance patient health and reduce healthcare costs.
FAQ
What is the current stock price of BETTER THERAPEUTICS (BTTX)?
What is the market cap of BETTER THERAPEUTICS (BTTX)?
What does Better Therapeutics Inc. do?
How do Better Therapeutics' solutions work?
What makes Better Therapeutics' approach unique?
Can Better Therapeutics' products be used with other treatments?
What recent achievements has Better Therapeutics made?
How does Better Therapeutics impact healthcare costs?
What evidence supports Better Therapeutics' products?
Who can benefit from Better Therapeutics' solutions?
What is the financial condition of Better Therapeutics?
What is the mission of Better Therapeutics?
